Annovis Bio, Inc. (ANVS) announced it received a notice from the New York Stock Exchange (NYSE) on October 29, 2026, indicating non-compliance with continued listing standards. The company failed to maintain an average market capitalization and stockholders' equity of at least $50 million.
Key Details
- Reason for Non-Compliance: The company's average market capitalization over a 30-day period was below $50 million, and its stockholders' equity was simultaneously below $50 million, violating Section 802.01B of the NYSE's Listed Company Manual.
- Financial Metrics: As of October 28, 2026, the company’s 30 trading-day average market capitalization was approximately $48.4 million. Its last reported stockholders' deficit was approximately $(4.3) million as of June 30, 2026.
- Next Steps: ANVS has 45 days to submit a compliance plan to the NYSE. If the plan is accepted, the company has a 9-month cure period to regain compliance. The stock will continue to trade on the NYSE but with an added ".BC" designation to indicate its status.